Analysts See $-0.31 EPS for VBI Vaccines Inc. (VBV)

March 4, 2018 - By Adrian Erickson

 Analysts See $ 0.31 EPS for VBI Vaccines Inc. (VBV)

Analysts expect VBI Vaccines Inc. (TSE:VBV) to report $-0.31 EPS on March, 23.They anticipate $0.07 EPS change or 29.17 % from last quarter’s $-0.24 EPS. After having $-0.30 EPS previously, VBI Vaccines Inc.’s analysts see 3.33 % EPS growth. The stock increased 2.66% or $0.13 during the last trading session, reaching $5.02. About 2,900 shares traded. VBI Vaccines Inc. (TSE:VBV) has 0.00% since March 4, 2017 and is . It has underperformed by 16.70% the S&P500.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $324.36 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

More news for VBI Vaccines Inc. (TSE:VBV) were recently published by:, which released: “Form 8-K VBI Vaccines Inc/BC For: Feb 19” on February 23, 2018.‘s article titled: “VBI Vaccines (VBIV) Prices Common Stock Offerings at $3.05/Share” and published on October 26, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: